Edwards Lifesciences Corporation (NYSE:EW) has earned an average rating of “Buy” from the twenty-two brokerages that are currently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $126.22.

A number of equities research analysts have recently issued reports on the stock. Cowen set a $135.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Sunday. BMO Capital Markets reissued a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research report on Friday. Canaccord Genuity reissued a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, November 29th. Deutsche Bank dropped their price target on shares of Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating for the company in a research report on Thursday, October 26th. Finally, Morgan Stanley dropped their price target on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th.

In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $108.86, for a total value of $576,958.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Schack Wesley W. Von sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $104.15, for a total transaction of $104,150.00. Following the completion of the transaction, the director now directly owns 2,622 shares in the company, valued at approximately $273,081.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 139,580 shares of company stock worth $14,849,205. Insiders own 2.13% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Wetherby Asset Management Inc. bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $206,000. Schwab Charles Investment Management Inc. increased its position in Edwards Lifesciences by 3.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 658,588 shares of the medical research company’s stock worth $77,872,000 after purchasing an additional 19,490 shares during the last quarter. First Mercantile Trust Co. bought a new stake in Edwards Lifesciences in the second quarter worth $723,000. Sigma Planning Corp bought a new stake in Edwards Lifesciences in the second quarter worth $217,000. Finally, Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences in the second quarter worth $1,206,000. Institutional investors own 81.82% of the company’s stock.

Edwards Lifesciences (NYSE EW) traded up $0.15 during mid-day trading on Monday, reaching $118.18. 1,313,423 shares of the company’s stock were exchanged, compared to its average volume of 1,641,483. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. Edwards Lifesciences has a fifty-two week low of $86.55 and a fifty-two week high of $121.45. The stock has a market cap of $24,977.50, a PE ratio of 32.69, a PEG ratio of 2.11 and a beta of 0.51.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million during the quarter, compared to analysts’ expectations of $833.85 million. During the same period last year, the company posted $0.68 EPS. Edwards Lifesciences’s revenue for the quarter was up 11.1% on a year-over-year basis. sell-side analysts forecast that Edwards Lifesciences will post 3.76 earnings per share for the current fiscal year.

Edwards Lifesciences announced that its Board of Directors has approved a stock buyback plan on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s board believes its stock is undervalued.

WARNING: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/11/edwards-lifesciences-corporation-ew-given-average-rating-of-buy-by-analysts.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.